|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We used CRISPR-DS to deeply sequence (mean Duplex depth ~3000×) the TP53 gene in 30 Pap tests from 21 women without cancer and 9 women with serous ovarian carcinoma with known TP53 driver mutations.
|
31839337 |
2020 |
|
Ovarian Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We retrospectively examined the overexpression of p53 in primary ovarian carcinoma, and its association with chemotherapeutic efficacy.
|
12668287 |
2003 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We demonstrated that in a unique population of HGSOC cancer cells with cancer stem cell properties, p53 protein aggregation is associated with p53 inactivation and platinum resistance.
|
25263447 |
2015 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We conclude that mutation and allelic loss of p53 are common and probably related events in the development of ovarian carcinoma.
|
7909153 |
1994 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Thus, considering the susceptibility to spontaneous mutations of the p53 gene in advanced ovarian carcinoma, the selection process resulting in emergence of p53 mutant tumors is a possible origin of resistance of ovarian carcinoma to DNA-damaging agents.
|
10437915 |
1999 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These findings demonstrate the potential of the p53 tumor suppressor gene therapy in human ovarian carcinoma.
|
8622881 |
1996 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These data confirm the findings of previous investigations describing TP53 mutation in ovarian carcinoma and demonstrate that archival paraffin-embedded tissues can be used for such analyses.
|
9301456 |
1997 |
|
Ovarian Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma.
|
8616869 |
1996 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The prognostic significance and nature of p53 dysfunction in ovarian carcinoma is unclear.
|
11064359 |
2000 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The objective of this study is to investigate whether wild-type TP53 status in high-grade serous ovarian carcinoma is associated with poorer survival.
|
23800698 |
2013 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The clinicopathological features of high-grade serous ovarian carcinoma (HGS-OvCa) patients with GOF p53 mutations were evaluated according to a comprehensive somatic mutation profile comprised of whole exome sequencing, mRNA expression, and protein expression profiles obtained from the Cancer Genome Atlas (TCGA).
|
23967324 |
2013 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study is to determine the status of p53 gene alteration in this distinct type of ovarian carcinoma.
|
11161858 |
2001 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to evaluate the relationship between p53 protein accumulation, p53 gene mutation and response to cisplatin-based chemotherapy in patients with ovarian carcinoma considering conventional clinicopathological parameters.
|
11125280 |
2001 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Targeted Genomic Sequencing Reveals Novel <i>TP53</i> In-frame Deletion Mutations Leading to p53 Overexpression in High-grade Serous Tubo-ovarian Carcinoma.
|
31177126 |
2019 |
|
Ovarian Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Studies on the p53 expression and outcome for women with ovarian carcinoma have produced conflicting results.
|
20629008 |
2010 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
|
26847329 |
2016 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Since the p53 gene has been identified as a determinant of response to chemotherapy in ovarian carcinoma in previous studies, we investigated the significance of the p53 status in response to topotecan as second-line therapy.
|
16127286 |
2005 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recently, this category of ovarian carcinoma has gained increasing attention owing to the recognition of morphological varieties of TP53-mutated high-grade ovarian carcinoma.
|
30636633 |
2019 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
|
30887755 |
2019 |
|
Ovarian Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
p53 inhibitor can increase the growth rate of subcutaneously transplanted tumor in nude mice. p53 inhibitor could decrease the expression of p53 and p21 at both mRNA and protein levels and increase the expression of MDM2 at both mRNA and protein levels in ovarian carcinoma transplanted subcutaneously in nude mice.
|
29565482 |
2018 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our study provides evidence that both germ line and somatic alterations of the p53 pathway influence the incidence and survival of ovarian carcinoma, and it underscores the importance of assessing the functionality of p53 in order to predict the sensitivity of platinum-based chemotherapies and patient outcome.
|
18172257 |
2008 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our NGS study of BM of ovarian carcinoma revealed a significant number of BRCA-mutations beside TP53, ATM and CHEK2 mutations.
|
28497333 |
2017 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our findings indicate that the adverse prognosis associated with TP53 and PIK3CA mutations in human cancers can be functionally replicated in mouse models of type I→type II OvCA progression.
|
23499052 |
2013 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our data indicate that parallel expression of MMP-2 epithelial/stromal cells and p53 may enhance cells invasion and metastasis in ovarian carcinoma.
|
23915071 |
2013 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations at the p53 tumor suppressor gene locus are a frequent genetic alteration associated with human ovarian carcinoma.
|
8005584 |
1994 |